{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:43:18Z","timestamp":1795020198360,"version":"4.10.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>TRAILBLAZER\u2010ALZ 6 (NCT05738486) is a multicenter, double\u2010blind, ongoing phase 3b study in early symptomatic Alzheimer's disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0843) were randomized 1:1:1:1 (standard + three alternative donanemab dosing arms). Primary outcome was relative risk reduction (RRR) of amyloid\u2010related imaging abnormalities with edema\/effusions (ARIA\u2010E) at 24\u00a0weeks assessed with Bayesian logistic regression. Amyloid plaque levels by positron emission tomography and serum donanemab pharmacokinetics were measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      ARIA\u2010E frequencies for standard, modified titration, dose skipping, and C\n                      <jats:sub>max<\/jats:sub>\n                      arms were 23.7%, 13.7%, 18.6%, and 18.3%, respectively, at 24\u00a0weeks and similar at 52\u00a0weeks: 24.2%, 15.6%, 18.6%, and 18.8%, respectively. Modified titration met the 24\u2010week primary outcome with 94% probability of achieving \u2265 20% RRR versus the standard arm. Modified titration also had significantly lower ARIA\u2010E severity, but similar cumulative exposure and mean amyloid reduction compared to the standard arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Gradual up\u2010titration of dose significantly reduced ARIA\u2010E risk while demonstrating comparable pharmacokinetics\/pharmacodynamics compared to standard dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>In TRAILBLAZER\u2010ALZ 6, the amyloid\u2010related imaging abnormalities\u2010edema\/effusions (ARIA\u2010E) frequency was 13.7% in the modified titration arm compared to 23.7% in the standard arm at week 24.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The modified titration arm met the primary endpoint of ARIA\u2010E relative risk reduction at 24 weeks versus the standard arm.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The modified titration versus standard arm at week 24 had comparable non\u2010ARIA\u2010E related safety profile, amyloid reduction, plasma phosphorylated tau217 reduction, cumulative exposure, and pharmacokinetics.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Data at week 52 were consistent with week 24 results.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.70062","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T06:44:17Z","timestamp":1743749057000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction"],"prefix":"10.1002","volume":"21","author":[{"given":"Hong","family":"Wang","sequence":"first","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Serap Monkul Nery","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ardayfio","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Otero Svaldi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Gueorguieva","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci E.","family":"Engle","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn A.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Collins","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[{"name":"Dementia Research Centre Department of Neurodegenerative Disease and the UK Dementia Research Institute UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology Massachusetts General Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[{"name":"Butler Hospital  Providence Rhode Island USA"},{"name":"Department of Neurology and Department of Psychiatry Alpert Medical School of Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_8_3_1","volume-title":"Kisunla (donaneamb\u2010azbt) [product insert]","year":"2024"},{"key":"e_1_2_8_4_1","volume-title":"Leqembi (lecanemab\u2010irmb) [package insert]","year":"2023"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0424-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"issue":"1","key":"e_1_2_8_11_1","first-page":"106","article-title":"Amyloid\u2010related imaging abnormalities\u2010haemosiderin (ARIA\u2010H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi HM","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.129"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.149.2.351"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.134"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3178"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2535"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"4","article-title":"S4\u2010Lecanemab for early Alzheimer's disease: long\u2010term outcomes, predictive biomarkers and novel subcutaneous administration. From: 16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24\u201027, 2023","volume":"10","author":"Van Dyck C","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13224"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082733"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0281-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13735"},{"key":"e_1_2_8_25_1","unstructured":"[FDA] Food and Drug Administration.Early Alzheimer's disease: developing drugs for treatment.Guidance for Industry. Draft guidance.2024. Accessed 3 December 2024.https:\/\/www.fda.gov\/media\/110903\/download"}],"updated-by":[{"DOI":"10.1002\/alz.70576","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000}}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:59:29Z","timestamp":1759957169000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/alz.70062"],"URL":"https:\/\/doi.org\/10.1002\/alz.70062","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70062"}}